biotech · Sleep · T-Cell Acute Lymphoblastic Leukemia/Lymphoma · BEAM
Beam Therapeutics
Beam Therapeutics is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker BEAM. Primary therapeutic focus areas include Sleep, T-Cell Acute Lymphoblastic Leukemia/Lymphoma, Sickle Cell D
Cambridge, USA HQ
2017 Founded
573 Employees
Public company Type
BEAM · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2017
- Employees
- 573
- Programs
- 10
- Drugs
- 14
- Patents
- 14
Allogeneic anti-CD7 CAR-T cells (BEAM-201)
Phase 1 · mab · T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Allogeneic anti-CD7 CAR-T cells (BEAM-201) for T-Cell Acute Lymphoblastic Leukemia/Lymphoma is a Phase 1 program (mab) at Beam Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code 24CT015, 25-023121, BTX-ALT-00
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Beam Therapeutics
- Phase
- Phase 1
- Modality
- mab
- Indication
- T-Cell Acute Lymphoblastic Leukemia/Lymphoma
- Status
- active
- Trials
- 1